Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Vinod P. Balachandran

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2956-223X; OpenAlex author ID A5060380153, A5061613758, A5129674673; NIH RePORTER profile ID 9594184. Sources: ClinicalTrials.gov.

Their work

Papers
39 (first author 2, last author 4)
Trials
1 (principal investigator on 1)
Grants
3
Labs led
1
Collaborators
156
Papers, trials and grants by year

2017: 3 papers · 2018: 4 papers · 2019: 3 papers, 1 trial · 2020: 3 papers · 2021: 4 papers, 1 grant · 2022: 7 papers · 2023: 2 papers · 2024: 1 paper · 2025: 7 papers, 1 grant · 2026: 5 papers, 1 grant

Papers 39

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  3. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  4. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  5. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  6. Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.70088↗
  7. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Last author DOI 10.1038/s41586-024-08426-5↗
  8. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Last author DOI 10.1038/s41586-024-08508-4↗
  9. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  10. Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Co-author DOI 10.1186/s12967-025-07381-7↗
  11. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  12. Radiomics in sporadic microsatellite instable, mismatch repair deficient and Lynch syndrome-associated pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.3389/fonc.2025.1584167↗
  13. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  14. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Last author DOI 10.1038/s41586-023-06063-y↗
  15. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  16. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  17. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  18. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Last author DOI 10.1038/s41586-022-04735-9↗
  19. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Co-author DOI 10.1126/scitranslmed.abc1600↗
  20. Reprogrammed Schwann Cells Organize into Dynamic Tracks that Promote Pancreatic Cancer Invasion. Co-author DOI 10.1158/2159-8290.cd-21-1690↗
  21. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adeno… Co-author DOI 10.1177/0003134821989050↗
  22. Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Co-author DOI 10.1245/s10434-022-11579-0↗
  23. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Co-author DOI 10.1007/s00261-020-02726-w↗
  24. Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Co-author DOI 10.1038/s41467-021-23237-2↗
  25. Scaling the immune incline in PDAC. First author DOI 10.1038/s41575-021-00475-9↗
  26. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  27. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  28. Immunological combination treatment holds the key to improving survival in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03332-5↗
  29. A Novel Model of Pancreatic Cancer Dormancy Reveals Mechanistic Insights and a Dormancy Gene Signature with Human Relevance Co-author DOI 10.1101/2020.04.13.037374↗
  30. Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. Co-author DOI 10.1007/s00261-018-1765-z↗
  31. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-019-02112-1↗
  32. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Co-author DOI 10.1053/j.gastro.2018.12.038↗
  33. Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Co-author DOI 10.1007/s00261-017-1407-x↗
  34. Does Second Reader Opinion Affect Patient Management in Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.1016/j.acra.2017.12.010↗
  35. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.09.001↗
  36. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Co-author DOI 10.1245/s10434-017-6323-3↗
  37. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. First author DOI 10.1038/nature24462↗
  38. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Co-author DOI 10.1158/1078-0432.ccr-17-0162↗
  39. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗

Trials 1

  1. Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery Principal investigator NCT04161755↗

Grants 3

  1. Biostatistics Core P50CA257881↗
  2. Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity R01CA262516↗
  3. Defining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapy U01CA224175↗

Closest collaborators

The 25 strongest of 156 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alice Chia-Chi Wei · 13 shared papers, 1 shared grant, 2021–2026 · strength 2.88
  2. William R. Jarnagin · 20 shared papers, 2017–2026 · strength 2.70
  3. Michael Ian D'Angelica · 19 shared papers, 2018–2026 · strength 2.65
  4. Eileen Mary O'Reilly · 13 shared papers, 1 shared grant, 2017–2026 · strength 2.64
  5. Kevin C. Soares · 15 shared papers, 2021–2026 · strength 2.53
  6. Jeffrey A. Drebin · 16 shared papers, 2019–2026 · strength 2.42
  7. T. Peter Kingham · 15 shared papers, 2018–2025 · strength 1.82
  8. Christine A. Iacobuzio–Donahue · 9 shared papers, 1 shared grant, 2017–2026 · strength 1.63
  9. Taha Merghoub · 4 shared papers, 1 shared grant, 2017–2025 · strength 1.53
  10. Marinela Capanu · 6 shared papers, 1 shared grant, 2019–2026 · strength 1.49
  11. Olca Baştürk · 6 shared papers, 1 shared grant, 2017–2026 · strength 1.36
  12. Wungki Park · 8 shared papers, 2020–2026 · strength 1.31
  13. Anna M. Varghese · 9 shared papers, 2017–2026 · strength 1.24
  14. Kenneth H. Yu · 8 shared papers, 2017–2026 · strength 1.13
  15. Caitlin A. McIntyre · 8 shared papers, 2019–2026 · strength 1.04
  16. Christopher H. Crane · 5 shared papers, 2021–2026 · strength 0.87
  17. T. Peter Kingham · 4 shared papers, 2025–2026 · strength 0.84
  18. Benjamin D. Greenbaum · 6 shared papers, 2017–2026 · strength 0.83
  19. Steven D Leach · 4 shared papers, 1 shared grant, 2017–2021 · strength 0.81
  20. Fiyinfolu O. Balogun · 4 shared papers, 2025–2026 · strength 0.76
  21. Peter J. Allen · 9 shared papers, 2017–2022 · strength 0.74
  22. Marsha Reyngold · 4 shared papers, 2021–2026 · strength 0.74
  23. Luis Alfonso Rojas · 4 shared papers, 2021–2025 · strength 0.70
  24. Jason Stuart Lewis · 1 shared grant, 2026 · strength 0.67
  25. Masataka Amisaki · 4 shared papers, 2022–2025 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.